{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:44:35Z","timestamp":1793807075737,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with different disease trajectories. Progression (PF-ILD) occurs in up to 50% of patients and is associated with increased mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for disease trajectories in different ILD. The course of disease was classified as significant (absolute forced vital capacity FVC decline\u2009&gt;\u200910%) or moderate progression (FVC decline 5\u201310%), stable disease (FVC decline or increase\u2009&lt;\u20095%) or improvement (FVC increase\u2009\u2265\u20095%) during time in registry. A second definition for PF-ILD included absolute decline in FVC % predicted\u2009\u2265\u200910% within 24 months <jats:italic>or<\/jats:italic> \u2265\u20091 respiratory-related hospitalisation. Risk factors for progression were determined by Cox proportional-hazard models and by logistic regression with forward selection. Kaplan-Meier curves were utilised to estimate survival time and time to progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Within the EXCITING-ILD registry 28.5% of the patients died (n\u2009=\u2009171), mainly due to ILD (n\u2009=\u200971, 41.5%). Median survival time from date of diagnosis on was 15.5 years (range 0.1 to 34.4 years). From 601 included patients, progression was detected in 50.6% of the patients (n\u2009=\u2009304) with shortest median time to progression in idiopathic NSIP (iNSIP; median 14.6 months) and idiopathic pulmonary fibrosis (IPF; median 18.9 months). Reasons for the determination as PF-ILD were mainly deterioration in lung function (PFT; 57.8%) and respiratory hospitalisations (40.6%). In multivariate analyses reduced baseline FVC together with age were significant predictors for progression (OR\u2009=\u20091.00, p\u2009&lt;\u20090.001). Higher GAP indices were a significant risk factor for a shorter survival time (GAP stage III vs. I HR\u2009=\u20099.06, p\u2009&lt;\u20090.001). A significant shorter survival time was found in IPF compared to sarcoidosis (HR\u2009=\u20090.04, p\u2009&lt;\u20090.001), CTD-ILD (HR\u2009=\u20090.33, p\u2009&lt;\u20090.001), and HP (HR\u2009=\u20090.30, p\u2009&lt;\u20090.001). Patients with at least one reported ILD exacerbation as a reason for hospitalisation had a median survival time of 7.3 years (range 0.1 to 34.4 years) compared to 19.6 years (range 0.3 to 19.6 years) in patients without exacerbations (HR\u2009=\u20090.39, p\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Disease progression is common in all ILD and associated with increased mortality. Most important risk factors for progression are impaired baseline forced vital capacity and higher age, as well as acute exacerbations and respiratory hospitalisations for mortality. Early detection of progression remains challenging, further clinical criteria in addition to PFT might be helpful.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-024-02731-3","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T13:02:21Z","timestamp":1709730141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Disease trajectories in interstitial lung diseases \u2013 data from the EXCITING-ILD registry"],"prefix":"10.1186","volume":"25","author":[{"given":"Katharina","family":"Buschulte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Kabitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hagmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hammerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Esselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Wiederhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Skowasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Stolpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Joest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Veitshans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"H\u00f6ffgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillen","family":"Maqhuzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Schwarzkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Karpavicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Polke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"H\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Somogyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Lederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Markart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"2731_CR1","doi-asserted-by":"crossref","unstructured":"Valeyre D, Duchemann B, Annesi-Maesano I et al. Interstitial lung diseases, in Respiratory Epidemiology, T. Welte, I. Annesi-Maesano, G. Viegi, and B. Lundb\u00e4ck,Eds., vol. 65 of ERSMonograph, Chap. 6, ERS, 2014.","DOI":"10.1183\/2312508X.erm6514"},{"issue":"2","key":"2731_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"American Thoracic Society and European Respiratory Society","year":"2002","unstructured":"American Thoracic Society and European Respiratory Society. American Thoracic Society\/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165(2):277\u2013304.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2731_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell D. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"2731_CR4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u2013e47.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2731_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/MCP.0000000000000908","volume":"28","author":"C Valenzuela","year":"2022","unstructured":"Valenzuela C, Cottin V. Epidemiology and real-life experience in progressive pulmonary fibrosis. Curr Opin Pulm Med. 2022;28(5):407\u201313. https:\/\/doi.org\/10.1097\/MCP.0000000000000908.","journal-title":"Curr Opin Pulm Med"},{"issue":"150","key":"2731_CR6","doi-asserted-by":"publisher","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","volume":"27","author":"V Cottin","year":"2018","unstructured":"Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, Skowasch D, Park JS, Poonyagariyagorn HK, Wuyts W, Wells AU. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076. https:\/\/doi.org\/10.1183\/16000617.0076-2018.","journal-title":"Eur Respir Rev"},{"issue":"10","key":"2731_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung diseases. N Engl J Med. 2020;383(10):958\u201368. https:\/\/doi.org\/10.1056\/NEJMra2005230.","journal-title":"N Engl J Med"},{"issue":"18","key":"2731_CR8","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK. INBUILD Trial investigators. Nintedanib in Progressive Fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1908681.","journal-title":"N Engl J Med"},{"issue":"5","key":"2731_CR9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Sch\u00f6nfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, G\u00fcnther A. RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476\u201386. https:\/\/doi.org\/10.1016\/S2213-2600(20)30554-3.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2731_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","volume":"8","author":"TM Maher","year":"2020","unstructured":"Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147\u201357. https:\/\/doi.org\/10.1016\/S2213-2600(19)30341-8.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"2731_CR11","doi-asserted-by":"publisher","first-page":"2102571","DOI":"10.1183\/13993003.02571-2021","volume":"60","author":"N Hambly","year":"2022","unstructured":"Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, Chong SG, MacIsaac S, Assayag D, Johannson KA, Fell CD, Marcoux V, Manganas H, Morisset J, Comes A, Fisher JH, Shapera S, Gershon AS, To T, Wong AW, Sadatsafavi M, Wilcox PG, Halayko AJ, Khalil N, Cox G, Richeldi L, Ryerson CJ, Kolb M. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60(4):2102571. https:\/\/doi.org\/10.1183\/13993003.02571-2021.","journal-title":"Eur Respir J"},{"issue":"2","key":"2731_CR12","doi-asserted-by":"publisher","first-page":"2002718","DOI":"10.1183\/13993003.02718-2020","volume":"57","author":"M Nasser","year":"2021","unstructured":"Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, Chalabreysse L, Fabre C, Marque S, Revel D, Thivolet-Bejui F, Traclet J, Zeghmar S, Maucort-Boulch D, Cottin V. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J. 2021;57(2):2002718. https:\/\/doi.org\/10.1183\/13993003.02718-2020.","journal-title":"Eur Respir J"},{"issue":"11","key":"2731_CR13","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","volume":"35","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M, Cottin V. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015\u201324. https:\/\/doi.org\/10.1080\/03007995.2019.1647040.","journal-title":"Curr Med Res Opin"},{"key":"2731_CR14","doi-asserted-by":"publisher","first-page":"123876","DOI":"10.1155\/2015\/123876","volume":"2015","author":"M Kreuter","year":"2015","unstructured":"Kreuter M, Herth FJ, Wacker M, Leidl R, Hellmann A, Pfeifer M, Behr J, Witt S, Kauschka D, Mall M, G\u00fcnther A, Markart P. Exploring clinical and epidemiological characteristics of interstitial Lung diseases: Rationale, Aims, and design of a nationwide prospective Registry\u2013The EXCITING-ILD Registry. Biomed Res Int. 2015;2015:123876. https:\/\/doi.org\/10.1155\/2015\/123876.","journal-title":"Biomed Res Int"},{"key":"2731_CR15","doi-asserted-by":"publisher","unstructured":"Buschulte K, Kabitz HJ, Hagmeyer L, Hammerl P, Esselmann A, Wiederhold C, Skowasch D, Stolpe C, Joest M, Veitshans S, H\u00f6ffgen M, Maqhuzu P, Schwarzkopf L, Hellmann A, Pfeifer M, Behr J, Karpavicius R, G\u00fcnther A, Polke M, H\u00f6ger P, Somogyi V, Lederer C, Markart P, Kreuter M. Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry. Respir Res. 2024 Jan 4;25(1):5. https:\/\/doi.org\/10.1186\/s12931-023-02588-y. PMID: 38178212; PMCID: PMC10765927.","DOI":"10.1186\/s12931-023-02588-y"},{"issue":"2","key":"2731_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","volume":"80","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Air\u00f3 P, Ananieva LP, Czirj\u00e1k L, Guiducci S, Hachulla E, Li M, Mihai C, Riemekasten G, Sfikakis PP, Kowal-Bielecka O, Riccardi A, Distler O. EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219\u201327. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217455.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2731_CR17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.13-1474","volume":"145","author":"CJ Ryerson","year":"2014","unstructured":"Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr, Collard HR. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723\u20138. https:\/\/doi.org\/10.1378\/chest.13-1474.","journal-title":"Chest"},{"issue":"1","key":"2731_CR18","doi-asserted-by":"publisher","first-page":"e0166462","DOI":"10.1371\/journal.pone.0166462","volume":"12","author":"V Cottin","year":"2017","unstructured":"Cottin V, Schmidt A, Catella L, Porte F, Fernandez-Montoya C, Le Lay K, B\u00e9nard S. Burden of idiopathic pulmonary fibrosis progression: a 5-Year longitudinal Follow-Up study. PLoS ONE. 2017;12(1):e0166462. https:\/\/doi.org\/10.1371\/journal.pone.0166462.","journal-title":"PLoS ONE"},{"issue":"1","key":"2731_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1378\/chest.13-2424","volume":"147","author":"AW Brown","year":"2015","unstructured":"Brown AW, Fischer CP, Shlobin OA, Buhr RG, Ahmad S, Weir NA, Nathan SD. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest. 2015;147(1):173\u20139.","journal-title":"Chest"},{"issue":"1","key":"2731_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-020-01335-x","volume":"21","author":"J W\u00e4lscher","year":"2020","unstructured":"W\u00e4lscher J, Witt S, Schwarzkopf L, Kreuter M. Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment - a German claims data analysis. Respir Res. 2020;21(1):73.","journal-title":"Respir Res"},{"key":"2731_CR21","doi-asserted-by":"publisher","first-page":"790204","DOI":"10.3389\/fphar.2021.790204","volume":"12","author":"SE Torrisi","year":"2021","unstructured":"Torrisi SE, Kahn N, W\u00e4lscher J, Polke M, Lee JS, Molyneaux PL, Sambataro FM, Heussel CP, Vancheri C, Kreuter M. Outcomes and incidence of PF-ILD according to different definitions in a Real-World setting. Front Pharmacol. 2021;12:790204. https:\/\/doi.org\/10.3389\/fphar.2021.790204.","journal-title":"Front Pharmacol"},{"issue":"6","key":"2731_CR22","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1136\/thoraxjnl-2020-216732","volume":"77","author":"X Ma","year":"2022","unstructured":"Ma X, Zhu L, Kurche JS, Xiao H, Dai H, Wang C. Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019. Thorax. 2022;77(6):596\u2013605. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-216732.","journal-title":"Thorax"},{"issue":"1","key":"2731_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12931-019-1037-7","volume":"20","author":"M Kreuter","year":"2019","unstructured":"Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS\u00ae trials. Respir Res. 2019;20(1):71. https:\/\/doi.org\/10.1186\/s12931-019-1037-7.","journal-title":"Respir Res"},{"issue":"5","key":"2731_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.humpath.2011.06.001","volume":"43","author":"LP Hariri","year":"2012","unstructured":"Hariri LP, Mino-Kenudson M, Shea B, Digumarthy S, Onozato M, Yagi Y, Fraire AE, Matsubara O, Mark EJ. Distinct histopathology of acute onset or abrupt exacerbation of hypersensitivity pneumonitis. Hum Pathol. 2012;43(5):660\u20138. https:\/\/doi.org\/10.1016\/j.humpath.2011.06.001.","journal-title":"Hum Pathol"},{"key":"2731_CR25","doi-asserted-by":"crossref","unstructured":"Kreuter M, Bendstrup E, Kondoh Y, et al. On behalf of the INBUILD trial investigators Acute exacerbations in patients with Progressive Fibrosing interstitial lung diseases: data from the INBUILD Trial.B94. LEARNING FROM REGISTRIES AND CLINICAL TRIALS IN ILD. American Thoracic Society; 2022. pp. A3428\u20138.","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A3428"},{"issue":"5","key":"2731_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1055\/a-2017-8971","volume":"77","author":"M Kreuter","year":"2023","unstructured":"Kreuter M, Behr J, Bonella F, Costabel U, Gerber A, Hamer OW, Heussel CP, Jonigk D, Krause A, Koschel D, Leuschner G, Markart P, Nowak D, Pfeifer M, Prasse A, W\u00e4lscher J, Winter H, Kabitz HJ. S1-Leitlinie Interdisziplin\u00e4re Diagnostik Interstitieller Lungenerkrankungen Im Erwachsenenalter [Consensus guideline on the interdisciplinary diagnosis of interstitial lung diseases]. Pneumologie. 2023;77(5):269\u2013302. https:\/\/doi.org\/10.1055\/a-2017-8971. German.","journal-title":"Pneumologie"},{"issue":"3","key":"2731_CR27","doi-asserted-by":"publisher","first-page":"1801587","DOI":"10.1183\/13993003.01587-2018","volume":"53","author":"SE Torrisi","year":"2019","unstructured":"Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C. The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multiCenter observational study. Eur Respir J. 2019;53(3):1801587. https:\/\/doi.org\/10.1183\/13993003.01587-2018.","journal-title":"Eur Respir J"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02731-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-024-02731-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02731-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T13:14:30Z","timestamp":1709730870000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-024-02731-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2731"],"URL":"https:\/\/doi.org\/10.1186\/s12931-024-02731-3","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"2 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted ethically in accordance with the World Medical Association Declaration of Helsinki and was approved by the Ethics Committee of the Medical Faculty of the University of Heidelberg, Germany (S-525\/2013) as well as by all local ethics committees of the participating centres. Informed consent to participate in the study was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KB received payment for lectures from Boehringer Ingelheim and a grant from Sarkoidose-Netzwerk e.V. LH received fees for consulting and lectures from Boehringer-Ingelheim, GSK, AstraZeneca, Pfizer and BMS. PH received fees for lectures from Galapagos, GSK, Boehringer Ingelheim, AstraZeneca, Roche. DS reports fees for lectures or consultations from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Janssen, MSD, Sanofi, all outside the submitted work. CS reports fees for lectures GSK, AstraZeneca, Boehringer Ingelheim, Berlin Chemie. MJ reports fees for lectures or consultations from AstraZeneca, Bencard, Boehringer Ingelheim, GSK, HAL Allergy, Sanofi, all outside the submitted work. SV reports fees from Berlin Chemie, GSK, Lilly, Pfizer, and Boehringer-Ingelheim. LS reports consulting fees from Galapagos. JB reports personal fees for lectures and consulting from Astra-Zeneca, Biogen, Boehringer-Ingelheim, BMS, Ferrer, Novartis, Roche, and Sanofi. AG reports grants, leture payments and\/or consulting fees from Boehringer Ingelheim, Roche, Lung Therapeutics and Pieris. MP has received payment or honoraria for lectures, presentations or educational events from Boehringer Ingelheim and AstraZeneca. VS received support for attending meetings from CSL Behring. PM received fees for consulting and lectures from Boehringer-Ingelheim and Roche. MK reports grants, consulting fees, or payment for lectures from Boehringer Ingelheim, Galapagos, AstraZeneca, BMS and Roche. All other authors have nothing to disclose. The registry was supported by an unrestricted grant by Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}